ALGN Should I Buy
-
$
0.000
0.000(0.000%)
At close0.000(0.000%)Aft-market
ET
Align Technology is not a strong buy right now for a beginner long-term investor with $50,000-$100,000 to deploy. The chart is constructive, but the stock is already near short-term resistance, options sentiment is mixed, and the new EU antitrust probe creates a real headline overhang. I would not call this an immediate buy today; the better call is to hold off or wait for a cleaner pullback or more clarity on the investigation.
ALGN is in an improving short-term uptrend. MACD histogram is positive and expanding, and the moving averages are bullish with SMA_5 > SMA_20 > SMA_200. RSI_6 at 64.8 is supportive but not yet overbought. Price at 184.54 is just above pivot 175.92 and very close to first resistance R1 at 183.95, with the next resistance at 188.91. That means upside is possible, but the stock is already pressing near a near-term ceiling rather than offering an obvious low-risk entry. The technical setup is constructive, but not compelling enough to justify an aggressive immediate long-term buy at this level.
Recent analyst sentiment is constructive. Leerink reiterated Outperform with a $230 target and said the EU case likely has limited fundamental impact. Piper Sandler raised its target to $235 and highlighted improving U.S. aligner volumes and teen demand. Evercore also raised its target to $220 and keeps Outperform. Analysts continue to point to multi-year growth drivers such as teen conversion, lab partnerships, ClinCheck improvements, and direct fab scaling. The next earnings report on July 29 could also be a catalyst if growth metrics hold up.
The biggest negative catalyst is the European Commission's formal antitrust investigation, which raises headline risk around tying Invisalign products to iTero scanners. The case could linger for a long time and may pressure sentiment even if the fundamental impact is limited. Morgan Stanley remains only Equal Weight, suggesting the Street is not fully unanimous. The stock trend model also points to weak near-term forward performance, including about -2.87% over the next month. Short-term resistance is close, which may cap upside immediately.
Latest quarter financials were not provided in the dataset, so I cannot assess the most recent reported quarter directly. The next earnings release is Q2 2026 on July 29 after market close. Based on the analyst commentary, the business is still viewed as having medium- to long-term revenue and margin opportunities, but I do not have the actual quarter season results here to confirm current growth rates.
Analyst sentiment is generally positive and has improved recently. Several firms have raised price targets: Evercore to $220, Piper Sandler to $235, Citi initiated at Buy with $240, and Leerink reiterated Outperform with $230. Morgan Stanley is more cautious at Equal Weight with a $188 target. Wall Street's pros see multiple long-term growth levers and believe the antitrust issue is more headline risk than fundamental damage. The cons view is that dental demand can be softer in a weak macro backdrop and the stock may already be pricing in much of the optimism.
